Tested medicines for drug-resistant lung tuberculosis
Part of Infections clinical trials.
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old
- You weigh more than 35 kg (about 77 lb)
- You have confirmed rifampicin-resistant lung TB from recent sputum or bronchoscopy tests within 3 months
- Chest imaging shows changes consistent with pulmonary tuberculosis
- You do not have certain health problems that can make treatment unsafe (heart rhythm issues, severe diabetes, or serious medication allergies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication combination (quabodepistat with other drugs) for people with drug-resistant pulmonary TB. It aims to find a shorter, safer, and more effective treatment.
This trial tests a combination of TB medicines (B-PaLMZ) for people with HIV who have their first episode of TB meningitis. It aims to find a better treatment option.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
Hear when a new Multidrug- and Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.